September 29, 2014: Daiichi Sankyo and Ambit Biosciences announced today they will merge in a deal valued up to $410 million. Daiichi will acquire all outstanding Ambit stock for $15 per share, about $315 million, and merge with a Daiichi subsidiary.
September 29, 2014: Drug giant Pfizer announced Sunday that its new lung cancer drug Xalkori has proved effective in shrinking tumors in those with an even a rare genetic mutation, according to data the firm presented at the European Society for Medical Oncology meeting in Madrid.
September 29, 2014: Merck & Co. said Monday that its newly approved melanoma cancer drug Keytruda has shown positive results in extending its immune system benefits to treat patients with bladder cancer as well.
September 29, 2014: Genentech's Perjeta, when added to Herceptin and chemotherapy, has been shown recently to extend the lives of patients with HER2-positive metastatic breast cancer (MBC) by 15.7 months compared to treatment with only Herceptin and chemotherapy.